Sibylle Loibl, Chief Executive Officer at the German Breast Group Research Company (GBG Forschungs GmbH), shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Hot from the Press: Now published in NEJM!
We are excited to share that the pivotal data from the DESTINY-Breast05 trial ‘Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer’ presented by Sibylle Loibl at SABCS2025, is now available in the New England Journal of Medicine.
This publication provides comprehensive evidence supporting T-DXd as a potential new post-neoadjuvant standard-of-care for patients with residual HER2+ early breast cancer after neoadjuvant therapy.”
Title: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
Authors: Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Cui-zhi Geng, Wuilbert Rodriguez Pantigoso, Francisco Javier Ramírez Godinez, Chuangui Song, Yuan Ching Chang, Augusto Antoniazzi, Shin-Cheh Chen, Zhigao Li, Zbigniew Nowecki, Joline Lim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Michael Untch, Charles E. Geyer Jr.
Read the Full Article on NEJM
More posts about SABCS2025.